BMY - Bristol-Myers Squibb Company Stock Price and Quote

BMY [NYSE]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	25.25	EPS (ttm)	2.95	Insider Own	0.07%	Shs Outstand	2.13B	Perf Week	2.57%
Market Cap	154.87B	Forward P/E	9.10	EPS next Y	8.19	Insider Trans	-17.54%	Shs Float	2.12B	Perf Month	2.08%
Income	6.33B	PEG	6.62	EPS next Q	1.99	Inst Own	79.40%	Short Float / Ratio	0.99% / 2.33	Perf Quarter	-5.41%
Sales	46.16B	P/S	3.36	EPS this Y	178.00%	Inst Trans	-0.72%	Short Interest	20.96M	Perf Half Y	0.98%
Book/sh	15.32	P/B	4.86	EPS next Y	1.92%	ROA	6.40%	Target Price	82.49	Perf Year	14.66%
Cash/sh	4.34	P/C	17.16	EPS next 5Y	3.82%	ROE	19.90%	52W Range	65.00 - 81.43	Perf YTD	3.57%
Dividend	2.28	P/FCF	15.87	EPS past 5Y	3.30%	ROI	9.40%	52W High	-8.49%	Beta	0.44
Dividend %	3.06%	Quick Ratio	1.30	Sales past 5Y	19.00%	Gross Margin	78.30%	52W Low	14.65%	ATR	1.41
Employees	32200	Current Ratio	1.40	Sales Q/Q	-3.50%	Oper. Margin	21.40%	RSI (14)	56.49	Volatility	2.44% 1.95%
Optionable	Yes	Debt/Eq	1.20	EPS Q/Q	8.50%	Profit Margin	14.30%	Rel Volume	0.97	Prev Close	74.53
Shortable	Yes	LT Debt/Eq	1.13	Earnings	Feb 02 BMO	Payout	67.90%	Avg Volume	9.00M	Price	74.52
Recom	2.30	SMA20	2.58%	SMA50	-0.30%	SMA200	0.25%	Volume	8,726,268	Change	-0.01%

Jan-17-23

Initiated

Cantor Fitzgerald

Overweight

$95

Nov-18-22

Initiated

Credit Suisse

Neutral

$78

Oct-10-22

Downgrade

Guggenheim

Buy → Neutral

Sep-14-22

Downgrade

Berenberg

Buy → Hold

$82 → $76

Jun-03-22

Downgrade

Raymond James

Outperform → Mkt Perform

Apr-06-22

Resumed

Morgan Stanley

Underweight

$64

Dec-17-21

Initiated

Goldman

Buy

$72

Dec-09-21

Resumed

Wells Fargo

Equal Weight

$58

Nov-19-21

Initiated

BMO Capital Markets

Outperform

$72

Nov-01-21

Downgrade

Argus

Buy → Hold

Show Previous Ratings

Feb-07-23 02:48PM	Bristol-Myers Squibb Company (NYSE:BMY) Q4 2022 Earnings Call Transcript Insider Monkey
Feb-06-23 01:00PM	Reflecting on Research in Genitourinary Cancers ACCESSWIRE
12:41PM	Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly Benzinga
09:00AM	Could This Indication Provide a Lift for Bristol Myers Squibb's Stock? Motley Fool
Feb-04-23 09:26AM	Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb? Motley Fool
07:14AM	Loading…
07:14AM	Bristol-Myers Squibb Full Year 2022 Earnings: In Line With Expectations Simply Wall St.
Feb-03-23 09:11AM	Company News for Feb 3, 2023 Zacks
06:59AM	Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference Business Wire
Feb-02-23 04:11PM	Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming Investor's Business Daily
02:59PM	Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales Zacks
02:00PM	Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript Motley Fool
12:58PM	Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics Zacks
11:00AM	Here's How to Trade Bristol-Myers Squibb After Earnings TheStreet.com
10:58AM	Bristol Myers Stock Rises as Profit Tops Estimates but Revenue Falls on Lower Revlimid Sales Barrons.com
10:55AM	Analyst Report: Bristol-Myers Squibb Company Morningstar Research
10:52AM	Loading…
10:52AM	UPDATE 1-Bristol Myers' profit beats on better-than-feared Revlimid sales Reuters
09:05AM	Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range Benzinga
08:55AM	Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook Investor's Business Daily
08:15AM	Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass Estimates Zacks
07:20AM	Bristol Myers Squibb sees revenue fall in Q4 MarketWatch
07:00AM	Bristol Myers Q4 earnings sag on lower Revlimid sales Reuters
06:59AM	Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022 Business Wire
06:59AM	Bristol Myers Q4 earnings sag on lower Revlimid sales Reuters
Feb-01-23 10:44AM	Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others Zacks
Jan-31-23 10:01AM	Qiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jan-29-23 08:53AM	2 Top Dividend Stocks to Buy in 2023 and Hold Forever Motley Fool
Jan-27-23 05:45PM	Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
11:28AM	Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store? Zacks
10:00AM	The Power of Dual Immunotherapy ACCESSWIRE
07:05AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia Business Wire
06:59AM	Loading…
06:59AM	Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis Business Wire
Jan-26-23 10:01AM	Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to Decline Zacks
08:00AM	iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors GlobeNewswire
06:59AM	Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia Business Wire
Jan-25-23 09:37AM	3 Buffett-Type Stocks to Buy Right Now Motley Fool
Jan-24-23 12:15PM	Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6% Zacks
Jan-23-23 05:50PM	Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-19-23 12:55PM	The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation To Expand With Amgens Commitment of $8 Million ACCESSWIRE
10:20AM	bluebird (BLUE) Stock Dives on Public Offering of Common Stock Zacks
08:30AM	The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgens Commitment of $8 Million Business Wire
05:49AM	5 Stocks You Can Confidently Invest $500 in Right Now Motley Fool
Jan-17-23 05:50PM	Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
07:30AM	Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug Motley Fool
Jan-14-23 10:03AM	A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them. The Wall Street Journal
08:00AM	These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well Simply Wall St.
Jan-13-23 12:42PM	Drug companies plan to raise prices on vital medicines to fund R&D, but they already spend more on shareholder returns than research MarketWatch
08:19AM	7 Dividend-Paying Large-Cap Stocks to Buy in January InvestorPlace
05:00AM	The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Honeywell, Sony, Airbnb and Republic Services Zacks
Jan-12-23 10:16AM	Top Stock Reports for Bristol-Myers Squibb, Honeywell International & Sony Zacks
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio Zacks
Jan-11-23 07:50AM	3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off Motley Fool
Jan-10-23 06:30PM	10 Most Fined Pharmaceutical Companies in the World Insider Monkey
05:50PM	Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks
07:00AM	Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their respectable 38% return over the last five years Simply Wall St.
Jan-09-23 08:44AM	The Years Biggest Healthcare Conference Starts Monday. What to Expect. Barrons.com
Jan-06-23 06:26PM	5 Top Pharma Stocks of 2022 to Buy for the Long Haul InvestorPlace
09:00AM	Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now? Zacks
06:00AM	With 75% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing Simply Wall St.
Jan-05-23 03:35PM	Biking the Globe for C2C4C ACCESSWIRE
09:00AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises Zacks
Jan-04-23 10:07AM	Investors Should Consider This Warren Buffett Advice in 2023 Motley Fool
09:00AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings Zacks
Jan-03-23 07:36PM	Analyst Report: Bristol-Myers Squibb Company Morningstar Research
05:50PM	Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
12:10PM	Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? Zacks
07:05AM	Bristol Myers Squibb to Present at J.P. Morgans 41st Annual Healthcare Conference Business Wire
06:59AM	Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York Business Wire
Jan-02-23 08:50AM	Income Investors Should Know That Bristol-Myers Squibb Company (NYSE:BMY) Goes Ex-Dividend Soon Simply Wall St.
Dec-31-22 08:00AM	Are Investors Undervaluing Bristol-Myers Squibb Company (NYSE:BMY) By 38%? Simply Wall St.
Dec-30-22 05:30AM	Drugmakers Spent Freely in 2022 to Protect Revenue The Wall Street Journal
Dec-28-22 05:50PM	Bristol Myers Squibb (BMY) Stock Moves -0.85%: What You Should Know Zacks
Dec-27-22 06:00PM	Bristol Myers Squibb (BMY) Stock Moves -0.38%: What You Should Know Zacks
08:38AM	Do Options Traders Know Something About Bristol-Myers (BMY) Stock We Don't? Zacks
06:00AM	Did Bristol-Myers Squibb Company (NYSE:BMY) Use Debt To Deliver Its ROE Of 20%? Simply Wall St.
Dec-26-22 09:00AM	Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know Zacks
Dec-23-22 09:02AM	You Can Boost Your Passive Income With These 3 Dividend Raises Motley Fool
06:01AM	Are Investors Undervaluing Bristol-Myers Squibb Company (NYSE:BMY) By 37%? Simply Wall St.
Dec-22-22 08:30AM	The Top Healthcare Stocks to Buy With $100 Motley Fool
Dec-20-22 01:35PM	Moments of Serendipity As Our Teams 'Light the Night' ACCESSWIRE
Dec-19-22 05:50PM	Bristol Myers Squibb (BMY) Stock Moves -0.45%: What You Should Know Zacks
12:00PM	St. Mary Medical Center gets $1M gift to boost its heart and vascular care center American City Business Journals
06:00AM	Is Bristol-Myers Squibb Company's (NYSE:BMY) 20% ROE Better Than Average? Simply Wall St.
Dec-15-22 08:30AM	2 Dividend Stocks to Buy and Hold Through 2023 and Beyond Motley Fool
06:59AM	Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023 Business Wire
06:00AM	Are Investors Undervaluing Bristol-Myers Squibb Company (NYSE:BMY) By 34%? Simply Wall St.
Dec-14-22 09:00AM	Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It Zacks
Dec-13-22 10:50AM	11 Best Low Beta Stocks to Buy Insider Monkey
Dec-12-22 05:50PM	Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know Zacks
01:19PM	10 Best Performing Healthcare ETFs in 2022 Insider Monkey
06:59AM	Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio Business Wire
04:30AM	The Zacks Analyst Blog Highlights Merck, Bristol-Myers Squibb and Deere Zacks
Dec-11-22 06:01AM	Investing in Bristol-Myers Squibb (NYSE:BMY) a year ago would have delivered you a 44% gain Simply Wall St.
Dec-09-22 01:25PM	Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & Deere Zacks
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick Zacks
Dec-08-22 04:16PM	Bristol Myers Squibb Announces Dividend Increase Business Wire
Dec-07-22 09:46AM	15 Most Creative Companies In The World Insider Monkey
09:00AM	Leading Health Stock With Rising Earnings Estimates Nears Buy Point Investor's Business Daily
07:00AM	Is Bristol-Myers Squibb Company's (NYSE:BMY) ROE Of 20% Impressive? Simply Wall St.
Dec-06-22 10:15AM	Cancer Care Milestone Reached in Lesotho ACCESSWIRE
Dec-03-22 09:00AM	Investing in Bristol-Myers Squibb (NYSE:BMY) a year ago would have delivered you a 49% gain Simply Wall St.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01	Option Exercise	0.00	2,543	0	2,543	Feb 03 07:18 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Dec 02	Option Exercise	0.00	2,637	0	44,603	Dec 06 07:32 PM
Elkins David V	EVP, Chief Financial Officer	Dec 02	Option Exercise	0.00	8,792	0	128,578	Dec 06 06:44 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Dec 02	Option Exercise	0.00	8,792	0	65,871	Dec 06 06:43 PM
Powell Ann	EVP, Chief Human Resources	Nov 09	Sale	80.45	16,250	1,307,312	34,226	Nov 14 06:57 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 07	Option Exercise	58.31	52,604	3,067,529	102,989	Nov 09 08:38 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Nov 07	Sale	78.88	45,910	3,621,381	57,079	Nov 09 08:38 PM
Caforio Giovanni	Board Chair and CEO	Sep 20	Sale	69.71	25,000	1,742,750	476,104	Sep 22 05:12 PM
Caforio Giovanni	Board Chair and CEO	Sep 15	Sale	71.84	50,000	3,592,000	501,104	Sep 16 05:12 PM
Powell Ann	EVP, Chief Human Resources	Sep 14	Sale	70.75	25,000	1,768,750	50,476	Sep 15 07:29 PM
Elkins David V	EVP, Chief Financial Officer	Sep 13	Option Exercise	48.49	123,277	5,977,702	223,737	Sep 15 07:29 PM
Elkins David V	EVP, Chief Financial Officer	Sep 13	Sale	71.30	133,951	9,551,167	100,460	Sep 15 07:29 PM
Weese Michelle	EVP, Corporate Affairs	Jul 01	Option Exercise	0.00	1,885	0	1,885	Jul 05 04:29 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Jul 01	Option Exercise	0.00	9,356	0	26,078	Jul 05 04:28 PM
Caforio Giovanni	Board Chair and CEO	Jun 13	Sale	74.04	30,000	2,221,200	551,104	Jun 14 05:58 PM
LEUNG SANDRA	EVP, General Counsel	Jun 06	Sale	74.89	65,000	4,867,850	308,627	Jun 07 05:49 PM
Haller Julia A	Director	Jun 03	Option Exercise	0.00	2,949	0	13,619	Jun 07 05:50 PM
Mily Elizabeth	EVP, Strategy & BD	Apr 01	Option Exercise	0.00	6,347	0	12,481	Apr 04 06:13 PM
Caforio Giovanni	Board Chair and CEO	Mar 21	Sale	71.52	25,000	1,788,000	581,524	Mar 23 07:43 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Mar 16	Option Exercise	57.00	47,305	2,696,612	93,613	Mar 18 05:50 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Mar 16	Sale	69.25	74,559	5,162,973	46,308	Mar 18 05:50 PM
Santiago Karen Murphy	SVP & Controller	Mar 14	Sale	69.19	6,577	455,096	16,704	Mar 16 07:32 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Mar 14	Sale	69.20	29,532	2,043,526	41,966	Mar 16 07:32 PM
Caforio Giovanni	Board Chair and CEO	Mar 10	Option Exercise	0.00	239,501	0	653,392	Mar 14 09:20 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10	Option Exercise	0.00	60,273	0	388,747	Mar 14 09:20 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10	Option Exercise	0.00	16,067	0	134,133	Mar 14 09:18 PM
BOERNER CHRISTOPHER S.	EVP, Chief Commercial Officer	Mar 10	Option Exercise	0.00	51,715	0	81,649	Mar 14 09:19 PM
Powell Ann	EVP, Chief Human Resources	Mar 10	Option Exercise	0.00	35,686	0	78,829	Mar 14 09:17 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Mar 10	Option Exercise	0.00	15,247	0	81,213	Mar 14 09:16 PM
Santiago Karen Murphy	SVP & Controller	Mar 10	Option Exercise	0.00	11,073	0	24,489	Mar 14 09:16 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10	Option Exercise	0.00	9,074	0	18,953	Mar 14 09:17 PM
Mily Elizabeth	EVP, Strategy & BD	Mar 10	Option Exercise	0.00	4,005	0	8,246	Mar 14 09:16 PM
Elkins David V	EVP, Chief Financial Officer	Mar 01	Option Exercise	0.00	24,577	0	132,034	Mar 03 05:33 PM
VESSEY RUPERT	EVP, Research & Early Dev.	Mar 01	Option Exercise	0.00	23,350	0	79,587	Mar 03 05:33 PM
Caforio Giovanni	Board Chair and CEO	Feb 24	Sale	67.00	30,000	2,010,000	453,455	Feb 28 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience